Anticancer Drugs Medicine Necitumumab Oncology Pharmacology Physiotherapy

Necitumumab (Mechanism of Action)

In this article we will discuss Necitumumab (Mechanism of Action)

In this article, we will discuss Necitumumab (Mechanism of Action). So, let’s get started.

Mechanism of Action

Necitumumab is a recombinant human lgG1 monoclonal antibody that binds to the human epidermal growth factor receptor (EGFR) and blocks the binding of EGFR to its ligands. Expression and activation of EGFR has been correlated with malignant progression, induction of angiogenesis, and inhibition of apoptosis. Binding of necitumumab induces EGFR internalization and degradation in vitro. In vitro, binding of necitumumab also led to antibody-dependent cellular cytotoxicity (ADCC) in EGFR-expressing cells. In in vivo studies using xenograft models of human cancer, including non-small cell lung carcinoma, administration of necitumumab to implanted mice resulted in increased antitumor activity in combination with gemcitabine and cisplatin as compared to mice receiving gemcitabine and cisplatin alone.


Based on population pharmacokinetic (popPK) analysis of serum concentration data from patients in clinical studies with Necitumumab, necitumumab exhibits dose-dependent kinetics. Following the administration of Necitumumab 800 mg on Days 1 and 8 of each 21 day cycle, the estimated mean total systemic clearance (CLtot) at steady state is 14.1 mL/h (CV=39%), the steady state volume of distribution (Vss) is 7.0 L (CV=31%) and the elimination half-life is approximately 14 days. The predicted time to reach steady state is approximately 100 days.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.